Cargando…
Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
The 3C-like (3CL) protease of the severe acute respiratory syndrome (SARS) coronavirus is a key enzyme for the virus maturation. We found for the first time that the mature SARS 3CL protease is subject to degradation at 188Arg/189Gln. Replacing Arg with Ile at position 188 rendered the protease resi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126698/ https://www.ncbi.nlm.nih.gov/pubmed/18845442 http://dx.doi.org/10.1016/j.bmc.2008.09.057 |
_version_ | 1783516202625138688 |
---|---|
author | Akaji, Kenichi Konno, Hiroyuki Onozuka, Mari Makino, Ayumi Saito, Hiroyuki Nosaka, Kazuto |
author_facet | Akaji, Kenichi Konno, Hiroyuki Onozuka, Mari Makino, Ayumi Saito, Hiroyuki Nosaka, Kazuto |
author_sort | Akaji, Kenichi |
collection | PubMed |
description | The 3C-like (3CL) protease of the severe acute respiratory syndrome (SARS) coronavirus is a key enzyme for the virus maturation. We found for the first time that the mature SARS 3CL protease is subject to degradation at 188Arg/189Gln. Replacing Arg with Ile at position 188 rendered the protease resistant to proteolysis. The R188I mutant digested a conserved undecapeptide substrate with a K(m) of 33.8 μM and k(cat) of 4753 s(−1). Compared with the value reported for the mature protease containing a C-terminal His-tag, the relative activity of the mutant was nearly 10(6). Novel peptide-aldehyde derivatives containing a side-chain-protected C-terminal Gln efficiently inhibited the catalytic activity of the R188I mutant. The results indicated for the first time that the tetrapeptide sequence is enough for inhibitory activities of peptide-aldehyde derivatives. |
format | Online Article Text |
id | pubmed-7126698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71266982020-04-08 Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant Akaji, Kenichi Konno, Hiroyuki Onozuka, Mari Makino, Ayumi Saito, Hiroyuki Nosaka, Kazuto Bioorg Med Chem Article The 3C-like (3CL) protease of the severe acute respiratory syndrome (SARS) coronavirus is a key enzyme for the virus maturation. We found for the first time that the mature SARS 3CL protease is subject to degradation at 188Arg/189Gln. Replacing Arg with Ile at position 188 rendered the protease resistant to proteolysis. The R188I mutant digested a conserved undecapeptide substrate with a K(m) of 33.8 μM and k(cat) of 4753 s(−1). Compared with the value reported for the mature protease containing a C-terminal His-tag, the relative activity of the mutant was nearly 10(6). Novel peptide-aldehyde derivatives containing a side-chain-protected C-terminal Gln efficiently inhibited the catalytic activity of the R188I mutant. The results indicated for the first time that the tetrapeptide sequence is enough for inhibitory activities of peptide-aldehyde derivatives. Elsevier Ltd. 2008-11-01 2008-09-26 /pmc/articles/PMC7126698/ /pubmed/18845442 http://dx.doi.org/10.1016/j.bmc.2008.09.057 Text en Copyright © 2008 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Akaji, Kenichi Konno, Hiroyuki Onozuka, Mari Makino, Ayumi Saito, Hiroyuki Nosaka, Kazuto Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant |
title | Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant |
title_full | Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant |
title_fullStr | Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant |
title_full_unstemmed | Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant |
title_short | Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant |
title_sort | evaluation of peptide-aldehyde inhibitors using r188i mutant of sars 3cl protease as a proteolysis-resistant mutant |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126698/ https://www.ncbi.nlm.nih.gov/pubmed/18845442 http://dx.doi.org/10.1016/j.bmc.2008.09.057 |
work_keys_str_mv | AT akajikenichi evaluationofpeptidealdehydeinhibitorsusingr188imutantofsars3clproteaseasaproteolysisresistantmutant AT konnohiroyuki evaluationofpeptidealdehydeinhibitorsusingr188imutantofsars3clproteaseasaproteolysisresistantmutant AT onozukamari evaluationofpeptidealdehydeinhibitorsusingr188imutantofsars3clproteaseasaproteolysisresistantmutant AT makinoayumi evaluationofpeptidealdehydeinhibitorsusingr188imutantofsars3clproteaseasaproteolysisresistantmutant AT saitohiroyuki evaluationofpeptidealdehydeinhibitorsusingr188imutantofsars3clproteaseasaproteolysisresistantmutant AT nosakakazuto evaluationofpeptidealdehydeinhibitorsusingr188imutantofsars3clproteaseasaproteolysisresistantmutant |